Figure][1] Jason S. Lewis, PhD Professor Jason S. Lewis holds the Emily Tow Chair at Memorial Sloan Kettering (MSK) in New York. He serves as deputy director of the Sloan Kettering Institute, ...

Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...

Recently, a collaborative effort among research centers in the United States and Europe resulted in the development of ...

Incidental findings from PET are common, induce unnecessary patient anxiety, and incur substantial costs to the health care system, with further diagnostic clarification potentially delaying important ...

The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took ...

Radiopharmaceuticals represent a promising new frontier in cancer therapy. In the United States, cancer is the second leading cause of death. There is an urgent need to develop new therapies to meet ...

Journal of Nuclear Medicine February 2026, jnumed.123.266357; DOI: https://doi.org/10.2967/jnumed.123.266357 ...

Journal of Nuclear Medicine February 2026, jnumed.125.271098; DOI: https://doi.org/10.2967/jnumed.125.271098 ...

Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP ...

PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations. The aim of the present study is to ...

Journal of Nuclear Medicine February 2026, jnumed.125.270083; DOI: https://doi.org/10.2967/jnumed.125.270083 ...

The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole ...